Calamos Advisors’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Calamos Advisors’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-100,000	Closed	-$981K	–	1485
2022 Q2	$981K	Hold	100,000	–	–	﹤0.01%	1020
2022 Q1	$982K	Hold	100,000	–	–	﹤0.01%	1038
2021 Q4	$990K	Hold	100,000	–	–	﹤0.01%	1005
2021 Q3	$994K	Hold	100,000	–	–	﹤0.01%	853
2021 Q2	$998K	Hold	100,000	–	–	﹤0.01%	828
2021 Q1	$1M	Buy	+100,000	New	+$999K	0.01%	766

Other funds holding EBACU

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

Calamos Advisors's EBACU Position: Q3 2022 in Review

Calamos Advisors sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2022, closing a stake of 100,000 shares — an estimated $981K sold.

Calamos Advisors first reported a position in EBACU in Q1 2021 and held it in 6 quarters. The position peaked at $1M in Q1 2021. 18 funds tracked by Wall St. Rank hold EBACU as of Q3 2022.

Calamos Advisors reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2022 after selling out during the quarter.
Calamos Advisors sold 100,000 European Biotech Acquisition Corp. Units shares in Q3 2022, an estimated $981K.
Calamos Advisors first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 6 quarters.
Calamos Advisors's European Biotech Acquisition Corp. Units position peaked at $1M in Q1 2021.
18 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2022.

Based on Calamos Advisors's 13F filing for Q3 2022, filed 24 Oct 2022.